Market closed
Mural Oncology plc/$MURA
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX
About Mural Oncology plc
Mural Oncology PLC is a clinical-stage oncology company whose entire business is focused on discovering and developing immunotherapies that may meaningfully improve the lives of patients with cancer. By leveraging its core competencies in immune cell modulation and protein engineering, It has developed a portfolio of novel, investigational cytokine therapies designed to address areas of unmet need for patients with a variety of cancers. Its product candidate, Nemvaleukin is an investigational, engineered interleukin-2 cytokine designed to capture and expand the therapeutic benefits of high-dose recombinant human IL-2 while mitigating its hallmark toxicities.
Ticker
$MURA
Sector
Trading on
Industry
Biotechnology
Headquarters
Dublin, Ireland
Employees
116
Website
MURA Metrics
BasicAdvanced
$42M
-
-$7.58
-
-
Price and volume
Market cap
$42M
52-week high
$4.74
52-week low
$0.95
Average daily volume
9M
Financial strength
Current ratio
5.838
Quick ratio
5.529
Long term debt to equity
1.752
Total debt to equity
5.71
Management effectiveness
Return on assets (TTM)
-36.68%
Return on equity (TTM)
-63.57%
Valuation
Price to book
0.29
Price to tangible book (TTM)
0.29
Price to free cash flow (TTM)
-0.318
Growth
Earnings per share change (TTM)
-39.02%
What the Analysts think about MURA
Analyst Ratings
Analyst ratings (Buy, Hold, Sell) for Mural Oncology plc stock.
MURA Financial Performance
Income Statement
Revenues and expenses
QuarterlyAnnual
Q3 24
QoQ growth
Revenue
$37B
-39.75%
Net income
$45B
107.52%
Profit margin
37.65%
6.78%
MURA Earnings Performance
Earnings per share (EPS)
Company profitability
QuarterlyAnnual
Q4 23
Q1 24
Q2 24
Q3 24
Q4 24
Actual
$3.69
$2.85
$2.45
$2.42
-
Expected
$3.55
$2.61
$2.05
$2.31
$3.94
Surprise
3.94%
9.20%
19.51%
4.63%
-
MURA News
AllArticlesVideos
Mural Oncology Provides Update on Phase 3 ARTISTRY-7 Trial of Nemvaleukin in Combination with KEYTRUDA® (pembrolizumab) in Patients with Platinum-Resistant Ovarian Cancer
GlobeNewsWire·3 weeks ago
Mural Oncology Announces Fourth Quarter and Year End 2024 Financial Results and Highlights Upcoming Clinical Milestones
GlobeNewsWire·1 month ago
Mural Oncology to Present at the TD Cowen 45th Annual Health Care Conference
GlobeNewsWire·2 months ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
FAQs
What’s the current market cap for Mural Oncology plc stock?
Mural Oncology plc (MURA) has a market cap of $42M as of April 17, 2025.
What is the P/E ratio for Mural Oncology plc stock?
The price to earnings (P/E) ratio for Mural Oncology plc (MURA) stock is 0 as of April 17, 2025.
Does Mural Oncology plc stock pay dividends?
No, Mural Oncology plc (MURA) stock does not pay dividends to its shareholders as of April 17, 2025.
When is the next Mural Oncology plc dividend payment date?
Mural Oncology plc (MURA) stock does not pay dividends to its shareholders.
What is the beta indicator for Mural Oncology plc?
Mural Oncology plc (MURA) does not currently have a Beta indicator.